VK2809, a novel liver-directed thyroid receptor agonist, produces durable reductions in liver fat in patients with non-alcoholic fatty liver disease: results of 4-week follow-up assessment from a 12-week phase 2 randomized, placebo-controlled trial

被引：0
|
作者：
Lian, Brian [1 ]
Loomba, Rohit [2 ]
Neutel, Joel [3 ]
Margaritescu, Carmen [4 ]
Homer, Ken [4 ]
Luk, Amy [1 ]
Mancini, Marianne [1 ]
Ji, Summer [1 ]
Barker, Geoff [1 ]
Severance, Randall [5 ]
Mohseni, Rizwana [6 ]
Bernard, David [7 ]
Dao, Michael [8 ]
机构：
[1] Viking Therapeut Inc, San Diego, CA USA
[2] Univ Calif San Diego, NAFLD Res Ctr, La Jolla, CA 92093 USA
[3] Orange Cty Res Ctr, Tustin, CA USA
[4] Integrium LLC, Tustin, CA USA
[5] Radiant Res, Chandler, AZ USA
[6] Catalina Res Inst, Montclair, NJ USA
[7] CHEAR, Bronx, NY USA
[8] SC Clin Res, Garden Grove, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
AS073
引用
收藏
页码：S53 / S53
页数：1
相关论文
共 13 条
  • [1] VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial
    Loomba, Rohit
    Neutel, Joel
    Bernard, David
    Severance, Randall
    Mohseni, Rizwana
    Dao, Michael
    Saini, Satinder
    Margaritescu, Carmen
    Homer, Ken
    Tran, Brian
    Mancini, Marianne
    Masamune, Hiroko
    Lian, Brian
    [J]. HEPATOLOGY, 2018, 68 (06) : 1448A - 1448A
  • [2] VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial
    Loomba, Rohit
    Neutel, Joel
    Mohseni, Rizwana
    Bernard, David
    Severance, Randall
    Dao, Michael
    Saini, Satinder
    Margaritescu, Carmen
    Homer, Ken
    Tran, Brian
    Mancini, Marianne
    Masamune, Hiroko
    Lian, Brian
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E150 - E151
  • [3] MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study
    Lawitz, Eric
    Bashir, Mustafa
    Shim-Lopez, Jennifer
    Lee, Jonathan
    Song, Ken
    Chen, Hubert
    Harrison, Stephen
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S132 - S132
  • [4] CHANGE IN LIVER FAT CONTENT AT 4 WEEKS ACCURATELY PREDICTS CHANGE IN LIVER FAT CONTENT AT 12 WEEKS IN NON-ALCOHOLIC STEATOHEPATITIS PATIENTS TREATED WITH AN FXR AGONIST: ANALYSIS FROM A 12-WEEK, RANDOMIZED, PLACEBO-CONTROLLED STUDY WITH MET409
    Jiang, Hanyu
    Chen, Hubert C.
    Bashir, Mustafa
    [J]. HEPATOLOGY, 2020, 72 : 900A - 900A
  • [5] Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and bodyweight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial
    Harrison, Stephen
    Tomah, Shaheen
    Suschak, John
    Roberts, Scot
    Yang, Jay
    He, Liang
    Georges, Bertrand
    Rodwell-Green, Lakisha
    Brown, Randy
    Harris, M. Scott
    Browne, Sarah
    [J]. JOURNAL OF HEPATOLOGY, 2023, 78 : S54 - S55
  • [6] EFFECTS OF A BALANCED GPL-1/GLUCAGON RECEPTOR DUAL AGONIST ON REDUCTION OF LIVER FAT AND WEIGHT LOSS: RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
    Harrison, Stephen A.
    Suschak, John
    Roberts, M. Scot
    Yang, Jay
    He, Liang
    Georges, Bertrand
    Rodwell-Green, Lakisha
    Brown, Randy
    Tomah, Shaheen
    Harris, M. Scott
    Browne, Sarah
    [J]. HEPATOLOGY, 2023, 77 (05) : E147 - E147
  • [7] THE NOVEL THYROID HORMONE RECEPTOR BETA AGONIST VK2809 SIGNIFICANTLY REDUCES LIVER FAT IN PATIENTS WITH NASH AND FIBROSIS, RESULTS FROM THE PRIMARY ENDPOINT OF THE ONGOING PHASE 2b VOYAGE STUDY
    Loomba, Rohit
    Rodriguez, Manuel
    Sheikh, Muhammad Y.
    Harrison, Stephen A.
    Rudraraju, Madhavi
    White, Alexander
    Maley, Elizabeth
    Lawitz, Eric
    Sanchez, William
    Jenders, Robert A.
    Goodwin, Jonathan
    Ravinuthala, Ravi
    Ladron-De-Guevara, Laura
    Brown, Michael
    Ji, Summer
    Barker, Geoffrey
    Steele, Rebecca Pedroza
    Mancini, Marianne
    Lian, Brian
    [J]. HEPATOLOGY, 2024, 79 (02) : E49 - E50
  • [8] Nigella sativa and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Results from a randomized, double-blind, placebo-controlled, clinical trial
    Darand, Mina
    Darabi, Zahra
    Yari, Zahra
    Saadati, Saeedeh
    Hedayati, Mehdi
    Khoncheh, Ahmad
    Hosseini-Ahangar, Behnam
    Alavian, Seyed Moayyed
    Hekmatdoost, Azita
    [J]. COMPLEMENTARY THERAPIES IN MEDICINE, 2019, 44 : 204 - 209
  • [9] LIK066 (LICOGLIFLOZIN), AN SGLT1/2 INHIBITOR, ROBUSTLY DECREASES ALT AND IMPROVES MARKERS OF HEPATIC AND METABOLIC HEALTH IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: INTERIM ANALYSIS OF A 12-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2a STUDY
    Harrison, Stephen A.
    Manghi, Frederico Perez
    Smith, William B.
    Alpenidze, Diana
    Aizenberg, Diego
    Burggraaf, Koos
    Chen, Chi-Ye
    Zuckerman, Eli
    Ravussin, Eric
    Charatcharoenwitthaya, Phunchai
    Cheng, Pin-Nan, II
    Katchman, Helena
    Klein, Samuel
    Ben-Ari, Ziv
    Mendonza, Anisha
    Zhang, Yiming
    Martic, Miljen
    Ma, Shenglin
    Kao, Sheena
    Tanner, Sandra
    Pachori, Alok
    He, Yan-Ling
    Ukomadu, Chinweike
    Sicard, Eric
    [J]. HEPATOLOGY, 2019, 70 (06) : 1482A - 1483A
  • [10] HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial
    Abdelmalek, Manal
    Choi, Jaeduk
    Kim, Youngmin
    Seo, Kyounghee
    Hompesch, Marcus
    Baek, Seungjae
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S124 - S124
12